Market Cap 555.75M
Revenue (ttm) 0.00
Net Income (ttm) -183.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,223,600
Avg Vol 1,178,344
Day's Range N/A - N/A
Shares Out 50.52M
Stochastic %K 26%
Beta -0.15
Analysts Strong Sell
Price Target $30.67

Company Profile

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formu...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 999 0075
Fax: 866 553 3269
Address:
55 Cambridge Parkway, Suite 901 East, Cambridge, United States
ALOSETE
ALOSETE Oct. 24 at 4:12 PM
$KALV Very cheap. Could run any day now.
0 · Reply
debilian
debilian Oct. 21 at 3:20 PM
$KALV Yo Ho Ho! and a bottle of rum!
0 · Reply
CrispDry
CrispDry Oct. 15 at 8:34 PM
$KALV what’s this after hours action? I show up 44 cents 800k traded
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 13 at 3:36 PM
$ALT $CCCC $IMRX $KALV $TNXP buy the dip of any of these five oversold biotech beauties and hold long 🚀
0 · Reply
GrandmaMoneybaggs
GrandmaMoneybaggs Oct. 8 at 4:29 PM
0 · Reply
Shakattack31
Shakattack31 Oct. 8 at 4:24 PM
$KALV glad i didn't sell yesterday
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 7 at 4:25 PM
$CRMD $GERN $IBRX $KALV $SLNO this is a great point. Holding Kalvista but even as a novel oral approval in a rare disease, this company is not getting the respect that an oncology launch would
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 7 at 1:44 AM
To us it appears that since commercial-stage oncology trades at significantly lower revenue multiples than non-oncology, oncology offers the better risk v. reward profile now that the XBI is nearing multi-year highs. Bios in both peer groups have near-tern data reads that may manifest in higher/lower revenues depending on the outcomes ($GERN $IBRX) Are we wrong? This is not investment advice. $KALV $CRMD $SLNO
0 · Reply
BlakeCanyon50
BlakeCanyon50 Oct. 6 at 9:27 PM
$KALV I took a fairly large position today. Can’t believe they dropped this in $10’s.
0 · Reply
TwongStocks
TwongStocks Oct. 6 at 8:01 PM
$KALV KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe https://www.businesswire.com/news/home/20251006039455/en/KalVista-Pharmaceuticals-Presents-New-Data-Highlighting-the-Potential-of-EKTERLY-sebetralstat-to-Transform-On-Demand-Hereditary-Angioedema-Treatment-in-Europe "With EKTERLY now approved in the European Union, we look forward to bringing this innovation to more people living with HAE—beginning with a launch in Germany this quarter followed by additional European launches in 2026 and beyond.”"
0 · Reply
Latest News on KALV
US FDA approves KalVista Pharma's swelling disorder drug

Jul 7, 2025, 6:37 AM EDT - 3 months ago

US FDA approves KalVista Pharma's swelling disorder drug


KalVista: Poised For Rare Disease Transformation

Apr 12, 2025, 12:42 AM EDT - 7 months ago

KalVista: Poised For Rare Disease Transformation


KalVista Appoints Jeb Ledell as Chief Operating Officer

Dec 16, 2024, 7:00 AM EST - 11 months ago

KalVista Appoints Jeb Ledell as Chief Operating Officer


ALOSETE
ALOSETE Oct. 24 at 4:12 PM
$KALV Very cheap. Could run any day now.
0 · Reply
debilian
debilian Oct. 21 at 3:20 PM
$KALV Yo Ho Ho! and a bottle of rum!
0 · Reply
CrispDry
CrispDry Oct. 15 at 8:34 PM
$KALV what’s this after hours action? I show up 44 cents 800k traded
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 13 at 3:36 PM
$ALT $CCCC $IMRX $KALV $TNXP buy the dip of any of these five oversold biotech beauties and hold long 🚀
0 · Reply
GrandmaMoneybaggs
GrandmaMoneybaggs Oct. 8 at 4:29 PM
0 · Reply
Shakattack31
Shakattack31 Oct. 8 at 4:24 PM
$KALV glad i didn't sell yesterday
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 7 at 4:25 PM
$CRMD $GERN $IBRX $KALV $SLNO this is a great point. Holding Kalvista but even as a novel oral approval in a rare disease, this company is not getting the respect that an oncology launch would
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 7 at 1:44 AM
To us it appears that since commercial-stage oncology trades at significantly lower revenue multiples than non-oncology, oncology offers the better risk v. reward profile now that the XBI is nearing multi-year highs. Bios in both peer groups have near-tern data reads that may manifest in higher/lower revenues depending on the outcomes ($GERN $IBRX) Are we wrong? This is not investment advice. $KALV $CRMD $SLNO
0 · Reply
BlakeCanyon50
BlakeCanyon50 Oct. 6 at 9:27 PM
$KALV I took a fairly large position today. Can’t believe they dropped this in $10’s.
0 · Reply
TwongStocks
TwongStocks Oct. 6 at 8:01 PM
$KALV KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe https://www.businesswire.com/news/home/20251006039455/en/KalVista-Pharmaceuticals-Presents-New-Data-Highlighting-the-Potential-of-EKTERLY-sebetralstat-to-Transform-On-Demand-Hereditary-Angioedema-Treatment-in-Europe "With EKTERLY now approved in the European Union, we look forward to bringing this innovation to more people living with HAE—beginning with a launch in Germany this quarter followed by additional European launches in 2026 and beyond.”"
0 · Reply
CH_Expat
CH_Expat Oct. 6 at 5:12 PM
$KALV Starter in single digits, would prefer 8s.
0 · Reply
edelhead
edelhead Oct. 6 at 2:26 PM
$KALV It's bizarro world again - Kalvista adds two talented people to the leadership team today and the stock goes down. What a disconnect! This stock will go up like crazy any time now, and I am and will be a Kalvista shareholder for that!!
3 · Reply
BioGem
BioGem Oct. 5 at 5:14 AM
$KALV I added more to my short since they took on debt. It means 2 negative things: 1-Cash is rapidly dwindling due to costly sales and marketing team and they are desperate, 2-Interest costs on this debt will be added to an already disastrous bottom line. Q3 numbers will be ugly.
0 · Reply
edelhead
edelhead Oct. 2 at 4:21 PM
$KALV the company adds a director, and announces approval of all proposals at the annual meeting - sounds very positive to me. The stock is tanking anyway - we live in bizarro world!
1 · Reply
TwongStocks
TwongStocks Oct. 2 at 11:33 AM
$KALV Bethany L. Sensenig, CFO at Radius Health, appointed to the Board of Directors. https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-appointment-bethany-l
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 1 at 11:49 AM
$FBIO it has happened before. $KALV was delayed for weeks a few months ago due to RFKJ’s cuts to the FDA. This shutdown and banana republic leadership in Washington isn’t helping manners. Hopefully we find out soon 🕰️
0 · Reply
buckdatrend13
buckdatrend13 Sep. 29 at 9:51 PM
$KALV Ten analysts have an average one-year price target of $32!!!!
1 · Reply
MakeMoneyAZ
MakeMoneyAZ Sep. 26 at 4:40 PM
$KALV Bought more. Whats the consensus on this? When we mooning?
0 · Reply
edelhead
edelhead Sep. 25 at 6:53 PM
$KALV This stock price reaction today is unbelievably ridiculous. You would think from the drop that there is immediate dilution coming at $12. BUT THAT IS NOT WHAT IS HAPPENING IN REALITY. I am frustrated for one reason - because I don't enough cash to buy more shares at this artificially and insanely depressed price!!
0 · Reply
edelhead
edelhead Sep. 25 at 4:05 PM
$KALV The market reaction today should be the opposite from what is happening. It seems like the potential future dilution is approx. 15%, but only if the stock price first goes up approx. 40%. And in the meantime the company can use the $125 mill to support its worldwide growth. Maybe I'm missing something, but I'm liking this convertible bond deal.
1 · Reply
CH_Expat
CH_Expat Sep. 25 at 3:53 PM
$KALV Almost there.
0 · Reply
redrussian
redrussian Sep. 25 at 1:54 PM
$KALV $ACU stopped out kalv sold acu 42.00
0 · Reply